Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2014-07-01
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-08-27 (study day 58.0); relationship: PROBABLE
mild
assessed
Mild FATIGUE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-11-02 (study day 125.0); relationship: POSSIBLE
Data queries
No data queries.